Acupuncture for chronic prostatitis
A systematic review and meta-analysis protocol

Tianzhong Peng, MSa, Ying Cheng, MSb, Yuhao Jin, MSa, Na Xu, MSa, Taipin Guo, MDb,*

Abstract

Background: Chronic prostatitis (CP) is a prevalent genitourinary condition. Considering its safety profile, acupuncture can be an option treating CP symptoms. The aim of this review is to undertake a systematic review to estimate the effectiveness and safety of acupuncture on CP.

Methods: We will search all randomized controlled trials for CP in August 2018 in the databases of MEDLINE, Cochrane Library, Web of Science, EMBASE, Springer, WHO International Clinical Trials Registry Platform (ICTRP), China National Knowledge Infrastructure (CNKI), Wan fang, Chinese Biomedical Literature Database (CBM), PsycInfo, Chinese Scientific Journal Database (VIP), and other available resources. Languages are limited as English and Chinese. Search terms used are will “acupuncture,” and “chronic prostatitis.” “non-bacterial prostatitis,” “abacterial prostatitis.” And duplicates will be screened. The primary outcomes consisted of improvement rate and pain relief evaluated by The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) index. Secondary outcomes include the recurrence rate and side effects, such as pneumothorax, discomforts, and infection.

Results: This study will demonstrate an evidence-based review of acupuncture for chronic prostatitis.

Conclusion: The study will provide clear evidence to assess the effectiveness and side effects of acupuncture for chronic prostatitis.

Ethics and dissemination: There is no requirement of ethical approval and it will be in print or disseminated by electronic copies.

PROSPERO registration number: CRD42018088834.

Abbreviations: CNKI = China National Knowledge Infrastructure, CP = chronic prostatitis, ICTRP = International Clinical Trials Registry Platform, IUSTI = The International Union against Sexually Transmitted Infections, MD = mean difference, NIH-CPSI = The National Institutes of Health Chronic Prostatitis Symptom Index, NRS = numerical rating scale, PRISMA-P = Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols, RCTs = randomized controlled trials, SPL = small particle of lecithin, SMD = standard mean difference, standard and ideal search, STRICTA = the Standards for Reporting Interventions in Controlled Trials of Acupuncture, TCM = traditional Chinese medicine, WBC = white blood cells, WHO = World Health Organization.

Keywords: acupuncture, chronic prostatitis, protocol, systematic review

1. Introduction

1.1. Description of the condition

Chronic prostatitis (CP) is a prevalent and common condition accompanied by lower urinary tract symptoms, CP is also a complex andrological dysfunction with a lifetime prevalence of 1.8% to 8% for men of all ages and races, most prominent in the elderly. It has ranked fourth among the 20 principal diagnostic diseases in the United States. The estimates also suggest that many cases might be under-diagnosed and undertreated by physicians. Most patients with CP have varying degrees and manifestations of voiding symptoms, a deferent duct obstruction, recurrent of urinary tract infections, and ejaculatory pain. Evidence also supports that there is a relationship between male infertility and prostatitis.

The National Institutes of Health (NIH) describes prostatitis into 4 categories. This research will cover randomized controlled trials (RCT) mainly for category III, or chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), which accounts for 90% cases of CP.

The pathogenesis of category III prostatitis is poorly understood; yet, substantial evidence suggests it is a multifactorial condition, where interactions exist between an infectious or inflammatory initiator, neurological injury, uric acid level, psychological factors, and dysfunction in the immune system.

General diagnosis is based on the presence of white blood cells, present in expressed prostate secretions (EPS), semen, or urine using a colorimetric assay, standard microbiological method, and culturing. Novel therapies include alpha-blocker, anti-inflammatory therapy, physiotherapy, neuroleptics, anti-anxiolytics, antidepressants, etc. However, treatment of noninflammatory CP is difficult, and pharmacological therapies proved unsuccessful in most cases.
Further, using anti-inflammatory drugs is associated with serious side-effects of gastrointestinal and cardiovascular disorders. So non-pharmacological treatments such as acupuncture[17–19] are therefore increasingly attractive. To date, acupuncture is often used for CP and chronic pain relief in east countries.[20]

To evaluate the evidence for the effectiveness of acupuncture in CP, we will undertake a systematic review and meta-analysis of RCTs. Based on the evidence of prospectively designed and RCTs in a well-defined population, we will use a validated outcome (The National Institutes of Health Chronic Prostatitis Symptom Index [NIH-CPSI]), and make treatment recommendations for physicians.

1.2. Description of the intervention

According to this approach, acupuncture’s effect will depend on specific acupoints, the stimulation intensity, frequency, and repetition. Then, we can provide a basis for defining the adequacy of acupuncture and sham interventions.

1.3. How the intervention might work?

Acupuncture, one of the most commonly used non-pharmacological therapies, has been considered a form of sensory nerve stimulation.[21,22] It has been used for relieving pain based on the evidence of biological mechanism. In east countries, acupuncture has been broadly employed for chronic conditions such as myofacial pain, muscle disorders, and neurological disorders.[23]

The theories of TCM believe[24] that the human body is a hierarchical and holistic organism, mutually interacting through meridian systems. The root cause of pain is stagnation of meridian system,[23] which will cause full or partial blockade neurovascular flows in regions. Acupuncture can help to regulate and redistribute the neurovascular flow in the body, thereby to improve neuromuscular dysfunction and relieve chronic fibromyalgia.

1.4. Why it is important to conduct this review?

We will systematically review and critically appraised the published literatures, and compare acupuncture with various types of control interventions. Different conclusion can be drawn, and the meta-analysis of RCTs will provide sufficient data.

1.5. Objectives

The primary goal of this systematic review is to appraise the effectiveness and safety of acupuncture on CP. Based on the evidence, we may recommend an effective therapy.

2. Methods

2.1. Study registration

PROSPERO registration number is CRD42018088834. This protocol report is structured according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement guidelines.[24]

2.2. Inclusion criteria for study selection

2.2.1. Types of study. To evaluate the efficacy of acupuncture on chronic CP, all relevant studies will be retrieved as full reports for detailed evaluation. We will include prospective RCTs of any form of acupuncture. The language will be limited to Chinese and English. The animal mechanism studies, case reports, non-RCTs, or RCT protocol are excluded.

2.2.2. Types of participants. There are no restrictions on population ages. The chronic prostatitis selected is type III with unknown causes. The definitions of chronic prostatitis or chronic prostate disorder are included. Patients with acute medical conditions are excluded.

2.2.3. Types of intervention. The review comprises clinical trials with the treatment of acupuncture. We will study the types of acupuncture including fine needle, floating needle, electro-acupuncture, etc. Any study that did not satisfy the inclusion criteria will be excluded. Studies to compare the effect of acupuncture stimulations methods or acupoints will be excluded. The sham procedure will be assessed to ensure reliable effects.

2.2.4. Types of outcome measures. The main outcome measure consists of NIH-CPSI index, expressed prostatic secretion (EPS) score, quality of life during intervention, and at follow-up. Secondary outcomes include the recurrence rate and side effects, and data on adverse events will be collected through observation by acupuncturists or self-reported by participants.

2.2.5. Data sources. We will search database in MEDLINE, EBASE, Cochrane Library, Springer, CNKI, Wanfang, WHO International Clinical Trials Registry Platform (ICTRP), CBM, and VIP. The languages are Chinese and English.

2.2.6. Search strategy. The following search keyword or combination subject terms are used: RCT (controlled clinical trial); acupuncture (e.g., “acupuncture” or “TCM acupuncture” or “fine needle acupuncture,” and “electro-acupuncture” or “fire needling”; chronic prostatitis; abacterial prostatitis; prostatodynia; prostatalgia; prostate pain). For Chinese databases, these search concepts will be precisely translated. The search strategies for Medline are summarized in Table 1.

| Table 1  |
|----------|
| Number  |
| Search terms                        |

1. Randomized controlled trial
2. Controlled clinical trial
3. Randomly
4. Randomized
5. Randomized
6. Trial
7. or/1–6
8. Chronic prostatitis
9. Abacterial prostatitis
10. Prostatodynia
11. Prostatitis
12. Prostate pain
13. or/8–12
14. Acupuncture
15. Acupoint
16. Meridian
17. Electro-acupuncture
18. Transcutaneous electrical nerve stimulation
19. Acupuncture catgut embedding
20. Acupressure
21. Cupping jar
22. Moxibustion
23. Auricular points
24. Abdominal acupuncture points
25. Scalp acupuncture points
26. Laser
27. Magnets
28. Bleeding
29. Acupuncture injection
30. Fire needle
31. Needle-knife
32. Superficial needling
33. or/14–33
34. 7 and 13 and 34
2.3. Data collection and analysis

2.3.1. Selection of studies. Selection, data extraction, and quality assessment will be performed independently by 2 reviewers (TZP and YC). All relevant articles of full text are investigated. When the 2 reviewers cannot agree on the selection process through consultations, the third reviewer (TPG) will ultimately make the decision. Translations of the full Chinese reports will be undertaken by YHJ. The primary selection process is shown in a PRISMA flow chart (Fig. 1)

2.3.2. Data extraction and management. Data will be extracted systematically by predefined, standardized methods on study design, participant characteristics, results, and statistical information. Evaluation score will be calculated using multiple criteria, including description of randomization, blinding, and withdrawals.

2.3.3. Assessment of risk of bias and reporting of study quality. Cochrane risk of bias tool will be used to score RCTs and assess for bias with the Cochrane Collaboration’s risk-of-bias assessment method and complete the Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA) checklist. Jadad Scale will be used to evaluate for methodological quality.

For unclear data, the author is contacted. And any study that does not satisfy the inclusion criteria will be excluded. The final decisions will be made by the third author (TPG).
2.3.4. Measures of treatment effect. We will use mean differences (MDs) with 95% confidence intervals (95% CIs) to analyze continuous data. Other forms of data will be changed into MD values. Risk ratio and random-effects models are used for significant heterogeneity.

2.3.5. Unit of analysis issues. Separate multiple meta-analyses for each treatment objective will be used. Multiple control groups are included, and pooled analyses of the control groups are used.

2.3.6. Management of missing data. For missing or incomplete data, we will try to contact the authors. If the data are still incomplete, we will screen it out.

2.3.7. Assessment of heterogeneity. Clinical heterogeneity will be explored through data synthesis, to identify any variations, Review Manager (version 5.3,Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2014)[27] and forest plot are used to illustrate the relative strength of curative effect. If significant heterogeneity is detected, secondary analyses based on variations in RCT characteristics will be used.

2.3.8. Assessment of reporting biases. If secondary analyses based on variations in RCT characteristics included, we will use funnel plots to evaluate reporting biases.

2.3.9. Data synthesis. The mean change in each of the outcome measures will be compared. Weighted mean differences (WMD) and a random-effects model with 95% CI will be calculated using Review Manager V5.3.[27]

2.3.10. Subgroup analysis. We will perform a subgroup analysis according to prede ned criteria.

2.3.11. Sensitivity analysis. A sensitivity analysis will be conducted according to predefined criteria.

3. Discussion

CP begins with some form of inductive factor within the prostate gland[27]: infection, injury, dysfunctional voiding, allergy, etc., which may cause in lammation or neurogenic damage in and around the prostate. If the treatment is insufficient, peripheral and central sensitization will happen.

It has been found recently that an altered autonomic nervous system response[28] in men with CP/CPPS. Since no reliable data or experiences to substantiate a traditional treatment, in patients who have developed a chronic condition, physiotherapy of acupuncture may provide benefit.

A report published[29] by WHO Consultation on Acupuncture states that acupuncture has been practiced on a wide range of physiological disorders including pain, infection, neurological disorders, urogenital disorders, etc. However, most of the mechanisms have not been able to explain how acupuncture might work.

This review will comprise RCTs with patients from different countries in either Chinese or English. The study will provide the first evidence that acupuncture may be considered an effective treatment for CP and how it is shown to be superior to pharmaceutical therapies in relieving symptoms and improving male reproductive function. Meanwhile, it will evaluate the secondary analyses to explore reasons for potential heterogeneity.

Author contributions

Data curation: Yuhao Jin.
Investigation: Na Xu.

Methodology: Na Xu.
Software: Yuhao Jin.
Supervision: Tainpin Guo.
Writing – original draft: Tianzhong Peng, Ying Cheng.
Writing – review and editing: Tainpin Guo.

References

[1] Schaefer EM. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: a meta-analysis. J Urol 2017;198:1190.
[2] Polackwich AS, Shokes DA. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer Prostatic Dis 2016;19:132–8.
[3] Li HJ, Kang DY. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: a meta-analysis. World J Urol 2016;34:1009–17.
[4] Le B, Schaefer AJ. Chronic prostatitis. Curr Opin Urol 2007;17:468–73.
[5] Cheng I, Wite JS, Jacobsen SJ, et al. Prostatitis, sexually transmitted diseases, and prostate cancer: the california men’s health study. PLoS One 2010;5:e8736.
[6] Sharp VJ, Takacs EB, Powell CR, et al. Prostatitis: diagnosis and treatment. Am Fam Physician 2010;82:397–406.
[7] Wagenlehner FM, van Till JW, Magri V, et al. National institutes of health chronic prostatitis symptom index (mph-cps) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2013;63:953–9.
[8] Vahleinscek W, Ludwing M, Wagenlehner FM, et al. Prostatitis - diagnostics and therapy. Aktuelle Urol 2013;44:117–23.
[9] Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 2011;305:78–86.
[10] Skvok AV, Oshepkepov VN, Egorov AA. Double-blind placebo-controlled trial of terazosin efficacy in patients with chronic abacterial prostatitis. Urologia 2005;47–53.
[11] Tkachuk VN, Shk A, Tkacuk IN, et al. Correction of erectile dysfunction in patients with chronic abacterial prostatitis. Urologia 2011;1:229–31.
[12] Roberts RO, Lieber MM, Rhodes T, et al. Prevalence of a physician-assigned diagnosis of prostatitis: the olmsted county study of urinary symptoms and health status among men. Urology 1998;51:578–84.
[13] Mcnaughton CM, Macdonald R, Wilt TJ, et al. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Ann Intern Med 2006;133:367–81.
[14] Nickel JC, Nigro M, Valiquette L, et al. Diagnosis and treatment of prostatitis in Canada. Urology 1998;52:797–802.
[15] Nickel JC. The three as of chronic prostatitis therapy: antibiotics, alpha-blockers and anti-inammatories. What is the evidence? BJU Int 2004;94:1230–3.
[16] Ogura K, Sengiku A, Miyazaki Y, et al. 1091 effects of add-on mirabegron on storage symptoms in men with lower urinary tract symptoms receiving alpha-1 blocker therapy. Eur Urol Suppl 2013;12:e1191.
[17] Chen R, Nickel JC. Acupuncture ameliorates symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. Urology 2003;61:1156–9.
[18] Lee SW, Liong ML, Yuen KH, et al. Acupuncture versus sham acupuncture for chronic prostatitis/chronic pelvic pain. Am J Med 2008;121:79.e1–7.
[19] Capodice JL, Jin Z, Bemis DL, et al. A pilot study on acupuncture for lower urinary tract symptoms related to chronic prostatitis/chronic pelvic pain. Chin Med 2007;2:1.
[20] Zhang Y, Zhang M, Wu Q. Clinical observations on the treatment of 80 chronic prostatitis patients with combined acupuncture and medicine. Acupuncture and Tuina (English Version) 2006;4:47–9.
[21] Johansson BB, Haker E, Von AM, et al. Acupuncture and transcutaneous nerve stimulation in stroke rehabilitation: a randomized, controlled trial. Stroke 2001;32:107–13.
[22] Chao AS, Chao A, Wang TH, et al. Pain relief by applying transcutaneous electrical nerve stimulation (tens) on acupuncture points during the first stage of labor: a randomized double-blind placebo-controlled trial. Pain 2007;127:214–20.
[23] Simma I, Gleditsch JM, Simma L, et al. Immediate effects of microsystem acupuncture in patients with oromandibular pain and craniomandibular disorders (cmd): a double-blind, placebo-controlled trial. Br Dent J 2009;207:E26.
[24] Chun-Huan Wu, Song ZB, Ai E. Shanghai research institute of acupuncture and meridian. J Acupuncture Tuina Sci 2011;4:100.
[25] Chang S. The meridian system and mechanism of acupuncture: a comparative review. Part 3: Mechanisms of acupuncture therapies. Taiwan J Obstet Gynecol 2013;52:171–84.
[26] Shamseer L, Moher D, Clarke M. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
[27] Lefebvre C, Manheimer E, Glanville J. Searching for studies. In: Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Ltd; 2008:188–235.
[28] Griffiths K, Denis L, Turkes A, et al. Phytoestrogens and diseases of the prostate gland. Baillieres Clin Endocrinol Metab 1998;12:625–47.
[29] Yılmaz U, Liu YW, Berger RE, et al. Autonomic nervous system changes in men with chronic pelvic pain syndrome. J Urol 2007;177:2170–4.
[30] Koo SY, Kim YS, Kang SK, et al. Report on the 5th WHO informal consultation on development of International Standard Acupuncture Points Locations. Korean J Meridian Acupoint 2007;24:113–27.